Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective

Robert G Gish1, Joanna P MacEwan2, Yutong Liu2

  • 1Robert G. Gish Consultants, LLC, San Diego, CA 92037, USA.

Insights

Primary biliary cholangitis (PBC) complications, including hepatic decompensation and liver transplantation, impose a significant economic burden. Effective patient management is crucial to reduce these high healthcare costs.

Area of Science:

  • Hepatology
  • Health Economics
  • Clinical Research

Background:

  • Primary biliary cholangitis (PBC) is associated with severe complications.
  • Hepatic decompensation and liver transplantation represent major clinical events in PBC progression.
  • The economic impact of these complications on healthcare systems and patients is substantial.

Purpose of the Study:

  • To evaluate the economic burden of primary biliary cholangitis (PBC)-related hepatic decompensation and liver transplantation.
  • To analyze costs associated with PBC disease progression using a large administrative claims database.
  • To identify the financial impact of complications requiring hospitalization and transplantation.

Main Methods:

  • Retrospective observational study utilizing Optum's Clinformatics® Data Mart Database.
  • Inclusion of patients aged ≥18 years with a primary biliary cholangitis (PBC) diagnosis.
  • Two cohorts were established: hepatic decompensation events and liver transplantation, analyzing associated costs.

Main Results:

  • The mean cost per hepatic decompensation event was $63,612.09, increasing to $116,424.25 with 30-day readmission.
  • The mean total cost for liver transplantation per patient was $328,336.60.
  • Hospitalization for liver transplantation represented the highest per-patient cost at $226,908.70.

Conclusions:

  • Primary biliary cholangitis (PBC) disease progression incurs a significant financial burden.
  • Hepatic decompensation and liver transplantation are high-cost events in PBC management.
  • Optimizing patient care strategies may alleviate the economic impact of advanced PBC.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
257